Bayer announced positive topline results from the global phase III QUASAR study evaluating the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein occlusion ...

ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion.

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of ...

A multinational study led by the LHON Study Group has revealed sustained visual improvements and a favorable safety profile ...

Nerinetide is under clinical development by NoNO and currently in Phase III for Acute Ischemic Stroke. According to GlobalData, Phase III drugs for Acute Ischemic Stroke have a 13% phase transition ...

Regeneron and Bayer report positive Phase III results for Eylea HD in macular edema following retinal vein occlusion, showing ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...

According to the MP Board’s date sheet for the 2024-25 session, Class 10 exams will take place in the morning shift from 9:00 ...

Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage ...